Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders

Nettis, Maria Antonietta

doi:10.1016/j.bbih.2021.100335

Cited by 22 publications

(14 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently with this background, the IL-1β and IL-6 blocking agents anakinra and tocilizumab showed protective effects against depression in COVID-19 survivors, with a parallel reduction of systemic inflammation (Benedetti et al, 2021a). Minocycline, an antibiotic tetracycline with broad brain and peripheral anti-inflammatory properties, has consistently showed superiority to placebo (Rosenblat and McIntyre, 2018), in particular for treatment-resistant depression with higher CRP (Nettis, 2021;Nettis et al, 2021). Overall, the available evidence suggests that anti-inflammatory add-on treatment may represent a well-tolerated and effective treatment, especially among subgroups of depressed patients with increased immune-inflammatory setpoints.…”

mentioning

confidence: 71%

Antidepressant psychopharmacology: is inflammation a future target?

Benedetti

Zanardi

Mazza

2022

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Raised inflammatory setpoints have been associated with major depression and its detrimental consequences on brain function, as they lead to increased production of cytokines, changes in gene expression and activated brain microglia. Three main lines of evidence support immune-inflammatory mechanisms as targets for the treatment of depression. First, higher inflammation hampers response to antidepressants, and effective antidepressant treatment decreases inflammation. Second, conventional antidepressants share immune-modulatory and anti-inflammatory properties, which could affect inflammation during the depression. Third, anti-inflammatory and immune-modulatory treatments proved superior to placebo in randomized controlled antidepressant trials. New targets and new pharmacologic treatment for immune-mediated inflammatory diseases have been identified and tested in several medical settings and interest is warranted for testing them as antidepressants.

show abstract

mentioning

confidence: 71%

Antidepressant psychopharmacology: is inflammation a future target?

Benedetti

Zanardi

Mazza

2022

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…[25]. Figure (10 ) When combined with Minocycline, E. coli and K. pneumoniae become more susceptible to antibiotics because Minocycline binds to a specific location in the 30S ribosomal subunit and prevents aminoacyl tRNA from attaching to the ribosomal acceptor site [26]. Figure (11) shows that there are substantial differences between Pyocyanin and antibiotics, and that Pyocyanin combined with Meropenem is more effective than Pyocyanin alone.…”

Section: Discussionmentioning

confidence: 99%

Comparative study between standard pyocyanin and extracted pyocyanin and synergistic with antibiotics against multidrug bacteria isolated from different clinical samples

Dhairh

Al-Azawi

2022

ijhs

View full text Add to dashboard Cite

Background: Multidrug Resistance forms in Gram positive and Gram negative bacteria are difficult to treat, and medications to be taken with caution may be unsuccessful. The emergence of treat MDR Gram-negative and Gram-positive Infections bacterial is still a major issue. Aims: The goal of this study is reliable develop new agents or new treatment methods that are capable of overcoming drug resistance in these organisms. Methods: 536(85.3%) samples from out and inpatients who admitted to Al Diwaniyah Teaching Hospital in Diwaniyah city were collected from various site of infection , 92 (46%) Pseudomonas aeruginosa were investigated by a qualified consulting doctor. After cultivation in special media (MacConkey agar and Nutrient agar) to detect , Pseudomonas aeruginosa , the samples were identified using the Vitec 2 compact system, Pyocyanin was extracted by standard methods from Pseudomonas aeruginosa Principal antimicrobial compounds present in pyocyanin were identified by HPLC . Other pathogenic bacteria obtained for exposure to Pyocyanin like Escherichia coli , K. pneumoniae , S. aureus from laboratories These diagnosis was confirmed by Vitek 2 system . Serratia marcescens and Proteus mirabilis obtained from sputum patients with co- infection Covid 19.

show abstract

“…These might be explained by its antioxidant properties and its capacity to inhibit immune cell activity, apoptosis, and various inflammation-promoting enzymes [ 85 ]. Moreover, it inhibits specific pathways involved in the inflammatory mechanism of depression, such as the kynurenine and the p-38 pathways [ 86 ]. Minocycline’s antidepressant effect is also associated with the inhibition of microglial activation, strongly linked to neuroinflammation [ 87 ].…”

Section: Non-conventional Anti-inflammatory Drugsmentioning

confidence: 99%

Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression

et al. 2022

View full text Add to dashboard Cite

Since depression remains a major public health issue there is a constant need for new and more efficient therapeutic strategies based on the mechanisms involved in the aetiology of depression. Thus, the pathogenic link between depression and inflammation is considered to play a potential key role in the development of such therapies. This review summarizes the results of various pharmacological (non-steroidal anti-inflammatory drugs, aspirin, cyclooxygenase inhibitors, cytokine inhibitors, corticosteroids, statins, minocycline, N-acetyl cysteine, omega-3 fatty acids and probiotics) and non-pharmacological interventions (electroconvulsive therapy, physical exercise and psychological therapy) and outlines their efficacy and discusses potential challenges. Both conventional and non-conventional anti-inflammatory drugs showed promising results according to the specific group of patients. The pre-existing pro-inflammatory status was, in most cases, a predictor for clinical efficacy and, in some cases, a correlation between clinical improvement and changes in various biomarkers was found. Some of the non-pharmacological interventions (physical exercise and electroconvulsive therapy) have also showed beneficial effects for depressive patients with elevated inflammatory markers. Treatments with anti-inflammatory action may improve clinical outcomes in depression, at least for some categories of patients, thus opening the way for a future personalised approach to patients with unipolar depression regarding the inflammation-related mechanism.

show abstract

Minocycline in Major Depressive Disorder: And overview with considerations on treatment-resistance and comparisons with other psychiatric disorders

Cited by 22 publications

References 69 publications

Antidepressant psychopharmacology: is inflammation a future target?

Antidepressant psychopharmacology: is inflammation a future target?

Comparative study between standard pyocyanin and extracted pyocyanin and synergistic with antibiotics against multidrug bacteria isolated from different clinical samples

Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression

Contact Info

Product

Resources

About